

# Resource Summary Report

Generated by [kravitz2](#) on Jul 29, 2026

## PE anti-human EGFR

RRID:AB\_10896794

Type: Antibody

---

### Proper Citation

BioLegend Cat# 352904, RRID:AB\_10896794

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_10896794](http://antibodyregistry.org/AB_10896794)

**Proper Citation:** BioLegend Cat# 352904, RRID:AB\_10896794

**Target Antigen:** EGFR

**Host Organism:** mouse

**Clonality:** monoclonal

**Comments:** Applications: FC

**Antibody Name:** PE anti-human EGFR

**Description:** This monoclonal targets EGFR

**Target Organism:** human

**Clone ID:** Clone AY13

**Antibody ID:** AB\_10896794

**Vendor:** BioLegend

**Catalog Number:** 352904

**Alternative Catalog Numbers:** 352903

**Record Creation Time:** 20250819T233224+0000

**Record Last Update:** 20250820T053857+0000

---

### Ratings and Alerts

No rating or validation information has been found for PE anti-human EGFR.

No alerts have been found for PE anti-human EGFR.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Hosking MP, et al. (2025) Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy. *Cell stem cell*, 32(7), 1087.

Denk D, et al. (2025) IL-17RA signaling provides dual tumor-suppressor function during late-stage colorectal carcinogenesis. *Immunity*, 58(3), 701.

Barra JM, et al. (2024) Combinatorial genetic engineering strategy for immune protection of stem cell-derived beta cells by chimeric antigen receptor regulatory T cells. *Cell reports*, 43(11), 114994.

Shah Z, et al. (2024) Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. *Cell stem cell*, 31(6), 803.

Tian M, et al. (2023) Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma. *Cell reports. Medicine*, 4(10), 101212.

Bosse KR, et al. (2022) Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. *Cancer discovery*, 12(12), 2800.